Intech Investment Management LLC Buys Shares of 15,097 Organogenesis Holdings Inc. (NASDAQ:ORGO)

Intech Investment Management LLC purchased a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 15,097 shares of the company’s stock, valued at approximately $43,000.

A number of other institutional investors have also modified their holdings of ORGO. Pallas Capital Advisors LLC purchased a new position in shares of Organogenesis in the second quarter valued at approximately $38,000. Delap Wealth Advisory LLC purchased a new stake in shares of Organogenesis during the 2nd quarter worth $40,000. Allspring Global Investments Holdings LLC grew its stake in shares of Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after purchasing an additional 15,369 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Organogenesis by 46.1% in the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after buying an additional 7,678 shares during the last quarter. Finally, CWM LLC raised its stake in Organogenesis by 301.8% in the second quarter. CWM LLC now owns 25,617 shares of the company’s stock valued at $72,000 after buying an additional 19,242 shares in the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Organogenesis

In other Organogenesis news, CEO Gary S. Gillheeney sold 18,416 shares of Organogenesis stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $3.65, for a total transaction of $67,218.40. Following the transaction, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at $12,412,839.70. The trade was a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 36.90% of the company’s stock.

Organogenesis Trading Down 4.9 %

NASDAQ:ORGO opened at $3.50 on Tuesday. Organogenesis Holdings Inc. has a 1 year low of $2.16 and a 1 year high of $4.70. The stock has a market cap of $464.03 million, a P/E ratio of -58.33 and a beta of 1.73. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The stock has a 50-day simple moving average of $3.37 and a 200-day simple moving average of $2.97.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. During the same period in the prior year, the company posted $0.02 earnings per share. As a group, analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.